Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: Intraperitoneal versus subcutaneous treatment

Peritoneal Dialysis International

Volumn 16, Issue SUPPL. 1, 1996, Pages

  Scarpioni, Lino ^a   Ballocchi, Sergio ^a   Scarpioni, Roberto ^a   Cristinelli, Luciano ^a  

^a Ospedale Civile   (Italy)

Author keywords

Diabetes; Intraperitoneal insulin

Indexed keywords

CREATININE; GLUCOSE; INSULIN;

CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE CLEARANCE; DIABETES CONTROL; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029972970     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089601601s51     Document Type: Conference Paper

References (33)

1. Viglino G, Cancarini GC, Catizone L, et al. Ten years experience ofCAPD in diabetics: comparison of results with non-diabetics. Nephrol Dial Transplant 1994; 9:1443-8.
2. Scarpioni LL, Ballocchi S, Castelli A,et al. Continuous ambulatory peritoneal dialysis in diabetic patients. Contrib Nephrol 1990; 84:60-74.
3. Lameire N, Matthys D, Matthys E, Beheydt R. Effect of long-term CAPD on carbohydrate and lipid metabolism. Clin Nephrol 1988; 30(Suppl 1):S53-8.
4. Rizza RA, Gerich JE, Service PJ, et al. Control of blood sugar in insulin-dependent diabetes. Comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion and intensified conventional insulin therapy. N Engl J Med 1980; 303:1313-18.
5. Schade DS, Eaton RP, Friedman NM, Spenser WJ. Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia 1980; 19:35-9.
6. Nelson JA, Stephen R, Landou ST, et al. Intraperitoneal insulin administration produces a positive portal-systemic blood insulin gradient in unanesthetized swine. Metabolism 1982; 31:369-72.
7. Rizza RA, Mandarine LJ, Genest J,et al. Production of insulin resistance by hyperinsulinemia in man. Diabetologia 1985; 28:70-5.
8. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2 year follow up of the Helsinki policemen study population. Acta Med Scand 1985; 701(Suppl): 38-52.
9. Rubenstein AH, Pottenger LA, Mako M, et al. The metabolism of proinsulin by the liver. J Clin Invest 1972; 51:912-16.
10. Falholt K, Cutfield R, Alejandro R, et al. Influence of portal delivery of insulin on intracellular glucose and lipid metabolism. Metabolism 1991; 40:122-6.
11. Schade DS, Heaton RP. The peritoneum a potential insulin delivery route for a mechanical pancreas. Diabetes Care 1980; 3:299-324.
12. Micossi P, Bosi E, Cristallo M, et al. Chronic continuous intraperitoneal insulin infusion (CIPII) in type I diabetic patients non-satisfactorily responsive to continuous subcutaneous insulin infusion (CS II). Acta Diabetol Lat 1986; 23:155-64.
13. Scarpioni L, Ballocchi S, Castelli A, Scarpioni R. Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis. Comparison of intraperitoneal and subcutaneous administration.Perit Dial Int 1994; 14:127-31.
14. Mykkanen L, Kuusisto J, Haffner SM, et al. Hyperinsulinemia predicts multiple atherogenic changes in lipoproteins in elderly subjects.Arterioscler Thromb 1994; 14:518-26.
15. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320:702-6.
16. Twardowski ZJ. Insulin adsorption to peritoneal dialysis bags. Perit Dial Bull 1983; 3:113-16.
17. Johnson CA, Amidon G, Reichert E, Porter WR. Adsorption of insulin to the surface of peritoneal dialysis solution containers. Am J Kidney Dis 1983; 3:224-8.
18. Wideroe TE, Smeby LC, Berg KJ,et al. Intraperitoneal (125 I) insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 1983; 23:22-8.
19. Peetom JJ, Willekens FLA, Meinders AE. Absorption and biological effect of intraperitoneal insulin administration in patients with terminal renal failure treated by continuous ambulatory peritoneal dialysis (CAPD). Neth J Med 1985; 28:435-41.
20. Balducci A, Slama G, Rottembourg J, et al. Intraperitoneal insulin in uraemic diabetics undergoing continuous ambulatory peritoneal dialysis. Br Med J 1981; 283:1021-3.
21. Rottembourg J, Issad B, Allouache M, et al. Clinical aspects of continuous ambulatory and continuous cyclic peritoneal dialysis in diabetic patients. Perit Dial Int 1989; 9:289-94.
22. Beardsworth SF, Ahmad R, Terry E, Karim K. Intraperitoneal insulin: a protocol for administration during CAPD and review of published protocols. Perit Dial Bull 1988; 8:145-51.
23. Spotti D, Slaviero G, Larocca E, et al. Intermediary metabolism and glycemic control in insulin-dependent diabetic uremic patients treated by continuous peritoneal dialysis. Nephron 1988; 49:219-22.
24. Shapiro DJ, Blumenkrantz MJ, Levin SR, Coburn W. Absorption and action of insulin added to peritoneal dialysate in dogs. Nephron 1979; 23:174-80.
25. Khanna R, Oreopoulos DG. Peritoneal dialysis in diabetic end stage renal disease. J Diabet Complications 1989; 3:12-17.
26. Kemperman FAW, Vanleusen R, Vanliebergen FJ, et al. Continuous ambulatory peritoneal dialysis in patients with diabetic nephropathy. Neth J Med 1991; 38:236-45.
27. Lindblad AS, Nolph KD, Nowak JW, et al. A survey of the NIH CAPD registry population with end-stage renal disease attributed to diabetic nephropathy. J Diabet Complications 1988; 2:227-32.
28. Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L. Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients. Nephron 1986; 42:133-40.
29. Scarpioni LL, Poisetti PG, Ballocchi S, Bergonzi G. Selective peritoneal protein loss.Contrib Nephrol 1989; 70:318-24.
30. Schmitz O. Insulin-mediated glucose uptake in nondialyzed uremic insulin-dependent diabetic subjects. Diabetes 1985; 34:1152-9.
31. Bagdade JD, Dunn FL. Effects of insulin treatment on lipoprotein composition and function in patients with IDDM. Diabetes 1992; 41(Suppl 2):107-10.
32. Ruotolo G, Micossi P, Galimberti G, et al. Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes. Metabolism 1990; 39:598-604.
33. Manske CL, Thomas W, Wang Y, Wilson RF. Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. Kidney Int 1993; 44:617-21.